Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.34 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14279770 | 0.86 | BRPF1 (0.54) | BRPF1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL11003744 | 0.81 | SHMT2 (0.39) | ALDH1A1KDM4EMAPTSMN1; SMN2HPGD | |
| SCHEMBL17576257 | 0.79 | BRPF1 (0.62) | BRPF1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL8442790 | 0.77 | CA12 (0.47) | BRPF1ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL7852404 | 0.77 | CA12 (0.50) | ALDH1A1KDM4EMAPTSMN1; SMN2HPGD | |
| SCHEMBL17505180 | 0.76 | BRPF1 (0.63) | BRPF1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL1260741 | 0.75 | CCR2 (0.56) | ALDH1A1KDM4EMAPTSMN1; SMN2HPGD | |
| SCHEMBL2952256 | 0.74 | BRPF1 (0.51) | BRPF1ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL3862000 | 0.73 | HDAC1 (0.42) | ALDH1A1KDM4EMAPTSMN1; SMN2HPGD | |
| SCHEMBL17417873 | 0.73 | MAPT (0.50) | ALDH1A1KDM4EMAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7902229-B2 | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| EP-1807416-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1807415-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006048249-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1655295-A1 | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1655297-A1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | BRPF1 511/4885ALDH1A1 1492/4885KDM4E 1759/4885 |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | BRPF1 563/4885ALDH1A1 1448/4885KDM4E 2249/4885 |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | FLT1, KDR, FLT4 | BRPF1 511/4885ALDH1A1 1492/4885KDM4E 1759/4885 |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | KDR, FLT4, FLT1 | BRPF1 2008/4885ALDH1A1 619/4885KDM4E 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.